C. Toze

Matthew P Wright, M. Power, D. Hogge, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Positive impact of selective outpatient management of high-risk acute myelogenous leukemia on the incidence of septicemia.

S. Nantel, D. Forrest, K. Song, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Immunoglobulin heavy chain (IGH@) translocations negatively impact treatment-free survival for chronic lymphocytic leukemia patients who have an isolated deletion 13q abnormality.

H. Bruyèrè, C. Toze, A. Gerrie, 2012, Cancer genetics.

Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease

J. Lipton, S. Nantel, S. Nantel, 2005, Bone Marrow Transplantation.

Allografting for indolent lymphoid neoplasms.

D. Reece, J. Connors, S. Nantel, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Chronic Lymphocytic Leukemia Patients With Deletion 11q Have a Short Time to Requirement of First‐Line Therapy, But Long Overall Survival: Results of a Population‐Based Cohort in British Columbia, Canada

J. Connors, A. Karsan, H. Bruyèrè, 2017, Clinical lymphoma, myeloma & leukemia.

Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.

J. Kuruvilla, D. Hogge, Clayton A. Smith, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

CLL-clear sailing ahead for many, while rough waters remain for some.

C. Toze, A. Gerrie, 2014, Leukemia research.

platelet disorder with propensity to myeloid malignancy Five new pedigrees with inherited RUNX1 mutations causing familial

B. Leber, T. A. Lister, M. Poon, 2013 .

Early-onset autoimmune hepatitis is associated with a C4A gene deletion.

C. Toze, L. Scully, R. Goldstein, 1993, Gastroenterology.

Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens

D. Hogge, S. Nantel, D. Forrest, 2010, Bone Marrow Transplantation.

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia

S. Coutre, C. Shustik, C. Owen, 2017, Annals of Hematology.

A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemia.

L. Sehn, E. Haddad, D. Vinh, 2016, Current oncology.

Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.

L. Sehn, H. Bruyèrè, P. Tsang, 2020, Leukemia research.

Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin.

C. Currie, S. Nantel, C. Toze, 2000, Journal of hematotherapy & stem cell research.

Characterization of treatment and outcomes in a population-based cohort of patients with chronic lymphocytic leukemia referred for cytogenetic testing in British Columbia, Canada.

A. Karsan, H. Bruyèrè, Adam C. Smith, 2017, Leukemia research.

Granulomatous Myositis as a Manifestation of Chronic Graft-Versus-Host Disease: A Case Series and Review of the Literature.

C. Toze, T. Nevill, Y. A. Mourad, 2022, Clinical lymphoma, myeloma & leukemia.

Factors Predictive for Graft Failure Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia in a Population-Based Provincial Transplant Cohort

M. Power, R. Broady, D. Hogge, 2012 .

Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months)

J. Connors, M. Power, R. Broady, 2011, Leukemia & lymphoma.

Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20‐year cohort

J. Connors, M. Power, R. Broady, 2012, British journal of haematology.

Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials

J. Connors, C. Toze, A. Gerrie, 2012, Leukemia & lymphoma.

Ultrasensitive detection of NOTCH1 delCT mutations in chronic lymphocytic leukemia by ddPCR reveals high frequency of subclonal mutations and predicts clinical outcome in cases with trisomy 12.

D. Scott, S. Ben-Neriah, C. Steidl, 2020, The Journal of molecular diagnostics : JMD.

Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia

D. Horsman, H. Bruyèrè, D. Hogge, 2006, Leukemia & lymphoma.

Alemtuzumab in clinical practice: A British Columbia experience

L. Sehn, J. Connors, M. Noble, 2007, Leukemia & lymphoma.

The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants

D. Steinemann, Alison M. Male, J. Fitzgibbon, 2020, Nature Communications.

Allogeneic Stem Cell Transplant in First Complete Remission Overcomes the Poor Prognosis Associated with the FLT-3 Internal Tandem Duplication in Acute Myeloid Leukemia.

A. Brooks-Wilson, R. Brinkman, M. Power, 2007 .

Normal karyotype CALLA-positive adult pre-B ALL: dismal outcome with chemotherapy for patients with loss/gain of ABL1 and/or BCR FISH signals.

H. Bruyèrè, S. Nantel, D. Forrest, 2013, Clinical lymphoma, myeloma & leukemia.

Shifting to outpatient management of acute myeloid leukemia: a prospective experience.

D. Hogge, S. Nantel, D. Forrest, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Chronic lymphocytic leukemia patients with HLA-B27 referred for allogeneic hematopoietic stem cell transplantation do not have worse outcomes: Results of a population-based case series analysis in British Columbia, Canada.

H. Bruyèrè, C. Toze, A. Gerrie, 2019, Leukemia research.

Stem cell transplantation for myelofibrosis: a report from two Canadian centers

W Hasegawa, J. Lipton, D. Hogge, 2003, Bone Marrow Transplantation.

Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes.

R. Gascoyne, J. Connors, D. Hogge, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

CD56bright natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft-versus-host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results

S. Mostafavi, T. Panzarella, M. Aljurf, 2017, Haematologica.

Allogeneic haemopoietic stem cell transplantation for non-Hodgkin's lymphoma.

C. Toze, M. Barnett, 2002, Best practice & research. Clinical haematology.

Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial

T. Panzarella, G. Devins, Stephanie J. Lee, 2014 .

Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.

T. Panzarella, G. Devins, Stephanie J. Lee, 2020, The Lancet. Haematology.

Preservation of lower incidence of chronic lymphocytic leukemia in Chinese residents in British Columbia: a 26-year survey from 1983 to 2008

W. Au, D. Ip, V. Mak, 2014, Leukemia & lymphoma.

Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study.

D. Fairclough, T. Panzarella, M. Aljurf, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphoma.

J. Connors, K. Savage, T. Panzarella, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Excellent real‐world outcomes of adults with Burkitt lymphoma treated with CODOX‐M/IVAC plus or minus rituximab

L. Sehn, J. Connors, G. Slack, 2018, British journal of haematology.

Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation.

R. Gascoyne, L. Sehn, J. Connors, 2015, Clinical lymphoma, myeloma & leukemia.

Population-based characterization of the genetic landscape of chronic lymphocytic leukemia patients referred for cytogenetic testing in British Columbia, Canada: the role of provincial laboratory standardization.

A. Karsan, H. Bruyèrè, Adam C. Smith, 2014, Cancer genetics.

Updates from the 2017 American Society of Hematology annual meeting: practice-changing studies in untreated chronic lymphocytic leukemia

C. Owen, C. Toze, A. Christofides, 2018 .

Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma.

D. Scott, L. Sehn, K. Savage, 2019, Blood advances.

Hematopoietic Stem Cell Transplant (HSCT) as Primary Treatment for T-Cell Lymphobastic Lymphoma (T-LBL) : An Intention to Treat Analysis.

R. Gascoyne, J. Connors, D. Hogge, 2004 .

Outpatient Autologous Stem Cell Transplants for Multiple Myeloma: Analysis of Safety and Outcomes in a Tertiary Care Center.

M. Power, R. Broady, D. Hogge, 2019, Clinical lymphoma, myeloma & leukemia.

High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver.

R. Gascoyne, J. Connors, D. Reece, 2005, Blood.

Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors.

D. Horsman, H. Bruyèrè, D. Hogge, 2006, Cancer genetics and cytogenetics.

High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.

R. Gascoyne, J. Connors, D. Hogge, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose etoposide and cyclophosphamide.

D. Hogge, Clayton A. Smith, S. Nantel, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.

M. Power, Yunfeng Dai, D. Hogge, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia in the era of novel agents: Challenges, pitfalls and strengths

C. Toze, Steven J. Huang, 2018, Oncology Signaling.

Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors.

M. Power, R. Broady, D. Hogge, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

72 Allogeneic bone marrow transplantation for myelofibrosis due to agnogenic myeloid metaplasia (AMM) and essential thrombocytosis (ET): Experience of two bone marrow transplant centers

J. Lipton, D. Hogge, S. Nantel, 2003 .

Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission.

D. Horsman, D. Hogge, Y. Chalandon, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcome Of Patients With Double-Hit Lymphomas Treated With CODOX-M/IVAC + R Followed By Hematopoietic Stem Cell Transplantation In British Columbia

R. Gascoyne, L. Sehn, J. Connors, 2013 .

Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML

M. Power, S. Nantel, K. Song, 2008, Bone Marrow Transplantation.

Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.

M. Power, R. Broady, D. Hogge, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Regulatory T-cells drive immune dysfunction in CLL

D. Lad, M. Levings, Rosa V. Garcia, 2018, Leukemia & lymphoma.

in the first 100 patients treated in Vancouver primary refractory or relapsed Hodgkin lymphoma: long-term outcome High-dose chemotherapy and autologous stem cell transplantation for

R. Gascoyne, J. Connors, D. Reece, 2011 .

Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy

A. Tantiworawit, M. Power, R. Broady, 2012, Leukemia & lymphoma.

Long-term follow-up of patients undergoing auto-SCT for advanced germ cell tumour: a multicentre cohort study

N. Murray, D. Hogge, M. Seftel, 2011, Bone Marrow Transplantation.

Gemcitabine, Dexamethasone, and Cisplatin (GDP) As Secondary Chemotherapy In Relapsed/Refractory Peripheral T-Cell Lymphoma

R. Gascoyne, L. Sehn, J. Connors, 2013 .

Autologous Stem Cell Transplant Outcome in Classic Hodgkin Lymphoma Patients in the Era of Post-Transplant Brentuximab Vedotin Consolidation

F. Kuchenbauer, M. Power, S. Nantel, 2021, Blood.